Quality of life (VFQ‐25 General health) · proliferative diabetic retinopathy
1 finding from 1 review
Adverse events · proliferative diabetic retinopathy
1 finding from 1 review
Depression Hospital Anxiety and Depression Scale (HADS) or Beck Inventory Score (HADS score range from 0 to 21 and Beck Inventory Score range from 0 to 63) · Women with non‐metastatic breast cancer
1 finding from 1 review
Anxiety · Women with non‐metastatic breast cancer
1 finding from 1 review
Mood disturbance Profile of mood state (higher score indicates more mood disturbance, score range from 0 to 200) · Women with non‐metastatic breast cancer
1 finding from 1 review
QoL · Women with non‐metastatic breast cancer
1 finding from 1 review
Stress 1 month · Women with non‐metastatic breast cancer
1 finding from 1 review
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).
1 finding from 1 review